Illumina in the news

Illumina's Chief Legal Officer, Julie Ann Coletti, received multiple equity awards, including restricted stock units and performance stock units tied to company performance.

Illumina's TruPath Genome advances whole-genome sequencing by combining short-read accuracy with long-range data for simplified, high-accuracy genomic analysis.

Marcel Nelen's team at UMC Utrecht is evaluating Illumina's TruPath technology, finding it streamlines rare disease research with novel library preparation and enhanced phasing capabilities.

Illumina's stock has surged recently, but conflicting valuation models and ongoing risks are creating investor debate.

Illumina Inc. stock underperformed on Wednesday compared to its competitors.

Several Wall Street analysts upgraded various company stocks, including Illumina, Sagimet Biosciences, Figure Technology Solutions, and Martin Marietta Materials.

Illumina Director Keith Meister sold $57 million in stock as the company prepares to rejoin the S&P 500, driven by strong demand for its sequencing platform.

Roche Diagnostics launched the AXELIOS next-generation sequencing platform and an FDA-approved blood test for Alzheimer's, aiming to make advanced diagnostics more accessible and practical for everyday medicine.

Illumina's stock performance and revenue growth are strong, but organic growth and free cash flow face challenges, with future guidance influenced by external factors and debt considerations.

Bloom Energy, Everpure, and Illumina are being added to the S&P 500 index as part of its September rebalance.

Illumina's stock is significantly overvalued at $211.06, which is 59% above its GF Value™ of $132.76, amidst significant insider selling.

Illumina's stock surge is driven by strong clinical demand for its gene sequencing technology, but its high valuation and challenges in the research market raise questions about sustained growth.

Illumina's new five-year collaboration agreement with Novacyt S.A. aims to broaden its assay partnerships and strengthen its position in genomic testing amidst competitive pressures and high valuation.

Illumina and Everpure are joining the S&P 500, which will increase their institutional exposure, but long-term success for both depends on fundamental business performance.

Illumina, a provider of DNA analysis equipment, rejoined the S&P 500 due to increased demand for its technology in drug development and genetic research.

Illumina's new collaboration framework with Novacyt aims to expand its clinical sequencing capabilities and maintain revenue growth amidst market challenges.

Bloom Energy, Everpure, and Illumina are being added to the S&P 500, while The Trade Desk is being removed.

Bloom Energy, Illumina, and Everpure are set to join the S&P 500 index, leading to an immediate bump in their stock prices.

Illumina's stock performance shows strong returns, with intrinsic value suggesting undervaluation while market multiples indicate it is expensive.

Bloom Energy, Everpure, and Illumina are being added to the S&P 500 index this month.